Understanding how acute myeloid leukemia resists targeted therapies
Official title: Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML
Funded at Coriell Institute for Medical Research · NIH-11042140 · Data updated 2026-11-12
This study is looking at why some patients with acute myeloid leukemia (AML) stop responding to certain cancer treatments, and it aims to find new ways to help those patients by understanding the genes involved in this resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project start | March 3, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $405,192 |
| NIH project number | 5R01CA255221-05 |
| Project ID | NIH-11042140 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, particularly those with FLT3 mutations or who have experienced resistance to existing therapies.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research investigates the mechanisms behind acquired resistance to tyrosine kinase inhibitors in patients with acute myeloid leukemia (AML). Using advanced techniques like CRISPR, the study aims to identify specific genes that contribute to this resistance, particularly focusing on the FLT3 receptor and its mutations. By understanding these signaling pathways, researchers hope to develop more effective treatments for patients who do not respond to current therapies. The findings could lead to improved strategies for overcoming drug resistance in AML.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia who currently face challenges with drug resistance.
How similar studies have gone: Previous research has shown promising results in understanding drug resistance mechanisms in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Coriell Institute for Medical Research
Camden, United States Active
Researchers
- Principal investigator: Huang, Jian — Coriell Institute for Medical Research
- Study coordinator: Huang, Jian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.